AISym4MED Synthetic and scalable data platform for medical empowered AI
- Coordinator
- Associacao Fraunhofer Portugal Research, Portugal
- Runs
- 1 December 2022 to 30 November 2026
- Status
- Running
- EU funding
- €6.3m
- Total cost
- €6.3m
- Partners
- 16 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101095387
What the project is doing
In the project's own words, from its summary on CORDIS.
AISym4Med aims at developing a platform that will provide healthcare data engineers, practitioners, and researchers access to a trustworthy dataset system augmented with controlled data synthesis for experimentation and modeling purposes. This platform will address data privacy and security by combining new anonymization techniques, attribute-based privacy measures, and trustworthy tracking systems. Moreover, data quality controlling measures, such as unbiased data and respect to ethical norms, context-aware search, and human-centered design for validation purposes will also be implemented to guarantee the representativeness of the synthetic data generated.
Indeed, an augmentation module will be responsible for exploring and developing further the techniques of creating synthetic data, also dynamically on demand for specific use cases. Furthermore, this platform will exploit federated technologies for reproducing un-indentifiable data from closed borders, promoting the indirect assessment of a broader number of databases, while respecting the privacy, security, and GDPR-compliant guidelines.
The proposed framework will support the development of innovative unbiased AI-based and distributed tools, technologies, and digital solutions for the benefit of researchers, patients, and providers of health services, while maintaining a high level of data privacy and ethical usage. AISym4Med will help in the creation of more robust machine learning (ML) algorithms for real-world readiness, while considering the most effective computation configuration.
Furthermore, a machine-learning meta-engine will provide information on the quality of the generalized model by analyzing its limits and breaking points, contributing to the creation of a more robust system by supplying on-demand real and/or synthetic data. This platform will be validated against local, national, and cross-border use-cases for both data engineers, ML developers, and aid for clinicians’ operations.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Associacao Fraunhofer Portugal Research | Porto | Portugal | Coordinator |
| Timelex | Bruxelles / Brussel | Belgium | Participant |
| Zabala Brussels | Bruxelles / Brussel | Belgium | Participant |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
| Asociacion Instituto De Investigacion Sanitaria Biobizkaia | Barakaldo Bizkaia | Spain | Participant |
| Ayesa Ibermatica SA | San Sebastian Guipuzcoa | Spain | Participant |
| Consorcio Sanitario De L'alt Penedes Y Garraf (csapg) | Vilafranca Del Penedes | Spain | Participant |
| Instrumentacion Y Componentes SA | Zaragoza | Spain | Participant |
| Servicio Vasco de Salud Osakidetza | Vitoria-Gasteiz | Spain | Third party |
| Zabala Innovation Consulting SA | Mutilva Alta Navarra | Spain | Third party |
| Saidot Oy | Espoo | Finland | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da Fct | Caparica | Portugal | Participant |
| Universidade Do Porto | Porto | Portugal | Participant |
| Tiga Bilgi Teknolojileri Anonim Sirketi | Golbasi | Türkiye | Participant |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI